my country's multiple anti-coronavirus drugs enter clinical trials
Since the outbreak of the new crown pneumonia, my country has continuously researched and explored effective treatment methods in the medical treatment work, and has started the research and development of anti-new crown virus drugs.
At present, a variety of drugs have completed preclinical research and entered the clinical trial stage.
VV116 is an oral nucleoside anti-coronavirus candidate drug jointly developed by many domestic scientific research institutions, including Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, and Xinjiang Institute of Physics and Chemistry, Chinese Academy of Sciences.
Preclinical pharmacodynamic studies have shown that VV116 has a significant inhibitory effect on the original virus strains and mutant strains of the new coronavirus, such as Delta virus, in vitro.
The research team of researcher Shen Jingshan of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and cooperative scientific research institutes found through experiments on adenovirus mouse models that oral administration of VV116 can reduce the virus titer below the detection limit, and can significantly improve the pathological changes of lung tissue in experimental model animals. A series of pre-clinical safety evaluation experiments show that VV116 has good safety and no genetic toxicity.
Shen Jingshan, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences: At present, we call it (VV116) a drug candidate. After the pre-clinical research is fully completed, the first clinical trial is approved in Uzbekistan, and this clinical trial is phase I, phase II, and phase III. The period is carried out at the same time.
In China, clinical trials are currently underway, and everyone is looking forward to the clinical data.
In another laboratory of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, researchers are studying another anti-coronavirus candidate drug FB2001, which is developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai University of Science and Technology, and Wuhan Institute of Virology, Chinese Academy of Sciences. Joint research and development with other units.
Researcher Liu Hong, the head of the research group, told reporters that they are mainly conducting innovative drug research on the 3CL proteolytic enzyme, a very important target in the replication cycle of the new coronavirus. FB2001 is an active compound they discovered from the experiment.
Liu Hong, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences: This compound (FB2001) has very good enzyme inhibitory activity and also has a good antiviral effect in the new coronavirus.
In March 2021, a phase I clinical study was conducted in the United States.
In this process, related research work was also published in "Science".
It is understood that for the research and development of anti-coronavirus drugs, the Shanghai Institute of Materia Medica, Chinese Academy of Sciences has achieved good results in the construction of screening systems, virtual screening, high-throughput screening, the discovery of lead compounds, and the subsequent development of small molecule drug candidates. Progress.
Li Jia, director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences: Both new drugs have completed preclinical studies and entered clinical trials, one in the United States and one in Uzbekistan for clinical studies. I believe that they have been continuously verified through clinical phase I, phase II, and phase III. If it can be proved that our medicine can protect patients with new crowns well, it will be a very important support for patients with new crowns around the world.
In addition, a new drug with my country’s independent intellectual property rights, "Prokalamide", has launched three clinical trials in Brazil since September 2020. The results show that the drug is effective for men and women inpatients with mild and moderate illness The hospitalization protection rate was 92%, and the risk of death for severely ill patients was reduced by 78%.
At present, Prokalamide is in the United States, Brazil, South Africa, Argentina, Malaysia, the Philippines and other countries to carry out a phase III global multi-center clinical trial for the treatment of patients with mild and moderate new coronary disease. It is also being treated in the United States, China, the Philippines, Brazil and other countries. The Phase III global multi-center clinical trial of patients with severe COVID-19, and the first patient enrollment and administration was completed at a clinical center in the United States on October 1 this year. The results of the clinical trial are expected to be disclosed in the first half of 2022.
Ma Liandong, head of the research and development of Prokruamide: Prokrulamide can inhibit the entry of new coronavirus into cells by two important proteins, one is called ACE2 and the other is called TMPRSS2.
Prokalamide can adjust the levels of these two proteins and make them drop, so that it will prevent the virus from entering the cell from outside the cell to replicate.
The second is to reduce the risk of death through the suppression of inflammatory molecular storms. These are our two most important mechanisms, which are independently developed and completed by our own team.